Clinical Trials
Presently, there are no approved disease-modifying treatments for FTD, though a number of clinical trials are underway. These clinical trials are led by various drug sponsors, and a subset of FPI clinical sites are enrolling patients into these studies. The active treatment trials targeting genetic forms of FTD and/or C9orf72-related ALS are summarized below:
Active treatment trials that target the genetic forms of FTD and/or ALS:
Progranulin (GRN)
- Alector Therapeutics: INFRONT-2 Phase 2 trial of AL001
- Alector Therapeutics: INFRONT-3 Phase 3 trial of AL001
- AviadoBio: ASPIRE-FTD Phase 1/2 trial of AVB-101
- Denali Therapeutics: Phase 2 trial of DNL593
- Passage Bio: upliFT-D Phase 1/2 trial of PBFT02
- Prevail Therapeutics: PROCLAIM Phase 1/2 trial of LY3884963
- Vesper Bio: SORT-IN-1 Phase 1 trial of VES001
C9orf72
MAPT and Other FTD-Causing Genes
There are currently no active treatment trials underway specific to MAPT or other genetic forms of FTD.
*Content is accurate as of May, 2024. The FPI does not oversee these studies nor endorse any specific trial. For the most current information, please visit clinicaltrials.gov.